Senna vs Dulcolax for Post-Surgery Constipation
What You Need to Know Before You Apply
What is the purpose of this trial?
This trial aims to determine which treatment better alleviates constipation after vaginal surgery for pelvic organ prolapse: oral senna tablets or Dulcolax suppositories. Participants will be divided into two groups to receive either senna, a natural laxative, or Dulcolax, a rectal suppository, to aid bowel movements post-surgery. Women scheduled for this type of surgery, who do not regularly use laxatives or have certain bowel conditions, are suitable candidates for this study. As an unphased trial, this study provides participants the opportunity to contribute to valuable research that may enhance post-surgical care for others.
Do I need to stop my current medications for this trial?
The trial does not specify if you need to stop your current medications. However, if you use laxatives regularly, you cannot participate in this trial.
Is there any evidence suggesting that this trial's treatments are likely to be safe?
Research shows that senna, a common over-the-counter laxative, is generally safe for short-term use. The FDA has approved it for treating constipation, and it typically works within 6 to 12 hours. Some people might experience side effects like stomach cramps, or less commonly, rectal bleeding or low potassium levels.
Dulcolax suppositories, containing bisacodyl, also offer quick relief from constipation. Common side effects include stomach cramps and dizziness. Avoid using them for more than a week without consulting a doctor to prevent further issues.
Both treatments are widely used and considered safe for short-term use. Always follow the dosage instructions and consult a healthcare provider if any severe side effects occur.12345Why are researchers excited about this trial's treatments?
Researchers are excited about these treatments for post-surgery constipation because they offer two distinct approaches. Senna tablets, a natural laxative, work by gently stimulating the intestines to promote bowel movements. This oral option is convenient for patients and offers a gradual yet effective relief. On the other hand, Dulcolax suppositories provide a more direct method by stimulating the bowel locally, which can lead to quicker results. Both treatments offer alternative methods to traditional oral laxatives, giving patients and doctors more options tailored to individual needs and responses.
What evidence suggests that this trial's treatments could be effective for post-surgery constipation?
This trial will compare the effectiveness of Senna and Dulcolax in treating post-surgery constipation. Studies have shown that both Senna, which participants may receive, and Dulcolax, another treatment option, effectively treat constipation. The FDA has approved Senna, and it is known to be safe and effective, particularly for post-surgery constipation. Research has shown that it helps reduce the time to the first bowel movement after pelvic surgery. Dulcolax, a rectal suppository containing bisacodyl, has also proven to speed up bowel recovery after abdominal surgeries. Both treatments aid bowel movements, making them useful for relieving constipation after surgery.678910
Who Is on the Research Team?
Candace Parker-Autry, MD
Principal Investigator
Wake Forest University Health Sciences
Are You a Good Fit for This Trial?
This trial is for women aged 18 or older who are scheduled for vaginal surgery to fix pelvic organ prolapse. It's not open to those under 18, unable to consent, using laxatives long-term, or with conditions like inflammatory bowel disease, irritable bowel syndrome, colorectal cancer, fistulas or concurrent bowel surgeries.Inclusion Criteria
Exclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants are randomized to receive either oral senna or rectal bisacodyl suppository for postoperative bowel regimen following vaginal reconstructive surgery
Follow-up
Participants are monitored for bowel function and satisfaction with treatment using various scales and questionnaires
What Are the Treatments Tested in This Trial?
Interventions
- Dulcolax Suppositories
- Senna Tab
Trial Overview
The study compares two methods of managing constipation after vaginal surgery: one group will use oral senna tablets and the other will use rectal bisacodyl suppositories. Women participating will be randomly assigned in equal numbers to either regimen.
How Is the Trial Designed?
2
Treatment groups
Experimental Treatment
Group A participants will be prescribed oral senna (Senokot; Atlantis Consumer Healthcare Inc., Bridgewater, NJ) 8.6mg tablets and be instructed to start with two tablets on the morning of Post Operative Day (POD)#1. Participant will continue taking two tablets on the daily. If no bowel movement on the morning of POD#3 participant may take 2 tablets in the morning and another 2 tablets that evening. The same can be replicated on POD#4. If no bowel movement on the morning of POD#5 participant may take magnesium hydroxide (Phillips' Milk of Magnesia; Bayer AG, Leverkusen, Germany) 30 mL by mouth and need to call the urology clinic for further instruction.
Group B participants will be prescribed bisacodyl rectal (Dulcolax Suppository; Sanofi S.A., Paris, France) 1 suppository to be placed rectally on the morning of Post Operative Day (POD)#1. Participant will continue placing a nightly rectal suppository until their first bowel movement. If no bowel movement by the morning of POD#5 participant may take magnesium hydroxide (Phillips' Milk of Magnesia; Bayer AG, Leverkusen, Germany) 30 mL by mouth and need to call the clinic for further instruction.
Find a Clinic Near You
Who Is Running the Clinical Trial?
Wake Forest University Health Sciences
Lead Sponsor
Published Research Related to This Trial
Citations
Safety and efficacy of laxatives after major abdominal surgery
Five RCTs with a total of 416 patients were included. Laxatives reduced the time to passage of stool (mean difference (MD) −0·83 (95 per cent ...
NCT06335797 | Optimization of Postoperative Bowel Habits
Dulcolax 1 suppository to be placed rectally on the evening of post operative day 1 and if needed, then continue using the same dose regiment until the post ...
Effect of bisacodyl on postoperative bowel motility in ...
Conclusion: Bisacodyl accelerated gastrointestinal recovery and might be considered as part of multimodal recovery programs after colorectal surgery.
Bisacodyl: A review of pharmacology and clinical evidence ...
Patients receiving bisacodyl had a significantly increased mean number of CSBMs per week over the treatment period, from 1.1 at baseline for ...
After Anal and Rectal Surgery | Patient Education
If you still have had no results after three days, take four Dulcolax tablets by mouth at one time. If this does not work within 12 hours, call your surgeon ...
DULCOLAX®
Use of Dulcolax with other laxatives may enhance gastrointestinal side effects. After taking DULCOLAX, avoid straining while passing a bowel motion. Dizziness ...
Laxative Suppositories for Constipation Relief
Dulcolax Suppositories interact at the source of the problem by softening your stools to deliver fast & effective relief from occasional constipation.
Bisacodyl - StatPearls - NCBI Bookshelf - NIH
[6][7] In a systematic review, bisacodyl has level 4 evidence regarding its safety and efficacy for chronic constipation.
Bisacodyl (Dulcolax, Fleet, and others): Uses, Side Effects, ...
Common side effects may include stomach discomfort, stomach cramps, or faintness. You should not use bisacodyl for more than one week unless ...
Dulcolax, Correctol (bisacodyl) dosing, indications, ...
Comment: Stimulant laxatives may increase the risk of mucosal ulceration or ischemic colitis when coadministered with bowel preps. sodium sulfate/potassium ...
Unbiased Results
We believe in providing patients with all the options.
Your Data Stays Your Data
We only share your information with the clinical trials you're trying to access.
Verified Trials Only
All of our trials are run by licensed doctors, researchers, and healthcare companies.